


Confident with your drug development strategy?

Stage 1: Reference Product & Development Strategy

Establish control early to reduce risk, support formulation decisions & prepare for regulatory scrutiny.




Outcome:

A patent-aware, impurity-controlled development programme built on scientifically-justified decisions.

Can you defend every impurity & specification?

Stage 2: Qualification, Stability & Registration

Generate the scientific justification needed to support specifications, stability claims and regulatory submission.



Outcome:

A submission-ready dossier supported by robust impurity qualification, stability evidence and regulatory rationale.

What supports your decision?

Whether selecting suppliers, controlling impurities, qualifying degradants, or preparing regulatory submissions, Lhasa solutions provide complementary evidence throughout the generic drug development workflow.

Supplier & route assessment

Derek, Sarah, Vitic & Vitic Q3D

Screen supplier routes, identify impurity risks and support sourcing decisions



Impurity purge assessment

Mirabilis

Calculate purge factors and strengthen impurity-control strategies



Degradation prediction

Zeneth & Lhasa Nitrites Data Sharing

Understand incompatibilities in your formulation and assess excipient-related nitrosamine risk



Toxicological qualification

Derek, Sarah & Vitic

Evaluate hazards and support scientifically justified impurity limits.



Metabolite comparison

Meteor

Predict and assess metabolite profiles to support impurity qualification strategies



When deeper expertise is needed

Consult Lhasa

Apply expert scientific assessment and interpretation to strengthen regulatory confidence.

